What are the diagnostic criteria and treatment options for insulinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Criteria and Treatment Options for Insulinoma

The definitive diagnosis of insulinoma requires a supervised 48-72 hour fast demonstrating Whipple's triad with specific biochemical criteria: blood glucose <55 mg/dL, insulin level >3 mcIU/mL, C-peptide ≥0.6 ng/mL, and proinsulin levels ≥5 pmol/L, followed by surgical resection as the optimal treatment with a 90% cure rate. 1

Diagnostic Approach

Clinical Presentation

  • Patients typically present with neuroglycopenic symptoms (confusion, lethargy, seizures) and may experience weight gain due to frequent eating to avoid hypoglycemia 1
  • Symptoms often occur during fasting, particularly in the morning 1

Diagnostic Testing

  • A supervised 48-72 hour fast is the gold standard first-line test for diagnosing insulinoma, continued until hypoglycemia occurs or the time limit is reached 1
  • Diagnostic criteria at the termination of the fast include:
    • Blood glucose <55 mg/dL 1
    • Insulin level >3 mcIU/mL (usually >6 mcIU/mL) 2, 1
    • C-peptide ≥0.6 ng/mL 2, 1
    • Proinsulin levels ≥5 pmol/L 2, 1
  • Elevated C-peptide levels help differentiate endogenous hyperinsulinemia (insulinoma) from exogenous insulin administration 1

Tumor Localization

  • Endoscopic ultrasound (EUS) is the preferred initial localization method with approximately 82% sensitivity for detecting pancreatic NETs 2, 1
  • Multiphasic CT or MRI scans should be performed to rule out metastatic disease 2, 1
  • For difficult cases, selective arterial calcium stimulation test (Imamura-Doppman procedure) can be considered, which involves injecting calcium into selective pancreatic arteries and measuring insulin levels in the hepatic vein 2, 1
  • Somatostatin scintigraphy is less useful for insulinomas than other pancreatic NETs and should only be performed if octreotide or lanreotide is being considered as a treatment 2

Treatment Options

Preoperative Management

  • Symptoms of hormonal excess must be treated to stabilize the patient before surgical excision 1
  • Glucose levels should be stabilized using:
    • Dietary management 1
    • Diazoxide - first-line medical therapy for managing hypoglycemia due to hyperinsulinism 1, 3
    • Everolimus - alternative for preoperative stabilization 1
  • Diazoxide is FDA-approved for management of hypoglycemia due to hyperinsulinism associated with inoperable islet cell adenoma or carcinoma 3

Surgical Management

  • Surgical resection is the optimal treatment for locoregional insulinomas, with a cure rate of 90% 2, 1
  • Surgical options depend on tumor location and size:
    • Enucleation is the primary treatment for exophytic or peripheral insulinomas 1
    • Laparoscopic enucleation for localized tumors within the body and tail of the pancreas 1
    • Distal pancreatectomy with preservation of the spleen for tumors in the body/tail that cannot be enucleated 1
    • Pancreatoduodenectomy for tumors in the head of the pancreas that are deep, invasive, or close to the main pancreatic duct 1

Medical Management

  • For patients who are not surgical candidates or with metastatic disease:
    • Diazoxide is effective for symptom control 1, 3
    • Everolimus may be considered 1
    • Somatostatin analogs should be used with extreme caution as they can worsen hypoglycemia 2, 1

Common Pitfalls and Caveats

  • Somatostatin analogs (octreotide, lanreotide) can worsen hypoglycemia in insulinoma patients by suppressing counterregulatory hormones and should be used with extreme caution 2, 1
  • Proton pump inhibitors can cause spuriously elevated chromogranin A levels, complicating diagnosis 2, 1
  • Diazoxide treatment requires close clinical supervision with careful monitoring of blood glucose and clinical response until the patient's condition has stabilized (usually several days) 3
  • If diazoxide is not effective in 2-3 weeks, it should be discontinued 3
  • Regular monitoring of urine glucose and ketones is necessary during prolonged diazoxide treatment, especially under stress conditions 3
  • Some insulinomas may present with normoglycemia after a prolonged fast but demonstrate glucose-stimulated hypoglycemia, so a "normal" 72-hour fast should be interpreted in light of clinical symptoms 4

References

Guideline

Diagnostic and Treatment Approach for Insulinoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.